Plasminogen

Alternative Names

  • PLG
  • Angiostatin
  • Microplasmin
Back to search Result
OMIM Number

173350

NCBI Gene ID

5340

Uniprot ID

P00747

Length

51,905 bases

No. of Exons

19

No. of isoforms

1

Protein Name

Plasminogen

Molecular Mass

90569 Da

Amino Acid Count

810

Genomic Location

chr6:160,702,192-160,754,096

Gene Map Locus
6q26

Description

Plasminogen is a circulating zymogen that is converted to the active enzyme plasmin. The main function of plasmin is the degradation of the insoluble fibrin blood clots that have been generated at a site of vascular injury. In addition, plasmin acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, angiogenesis, inflammation, tumor cell invasion, and metastasis.

Inherited PLG deficiency can be divided into two types: true PLG deficiency (type I, or hypoplasminogenemia) and dysplasminogenemia (type II). Additionally, it has been shown that homozygous or compound-heterozygous type I PLG deficiency is a major cause of a rare inflammatory disease affecting mainly mucous membranes in different body sites. The most common clinical manifestation is ligneous conjunctivitis. Other, less common manifestations are ligneous gingivitis, otitis media, ligneous bronchitis and pneumonia, involvement of the gastrointestinal or female genital tract, juvenile colloid milium of the skin, and congenital occlusive hydrocephalus.

Epidemiology in the Arab World

View Map
Variant NameCountryGenomic LocationClinvar Clinical SignificanceCTGA Clinical Significance Condition(s)HGVS ExpressionsdbSNPClinvar
NM_000301.3:c.1256+9T>CUnited Arab EmiratesNC_000006.12:g.160722576T>CBenignAssociationCoronary Artery Disease, Autosomal Dominant, 1NG_016200.1:g.25384T>C; NM_000301.3:c.1256+9T>C; NP_000292.1:p.?42521201175041

Other Reports

Jordan

Cleve et al. (1992) studied samples from 124 healthy unrelated Arabs from Amman were studied for AHSG, BF, F XIII B, GC, PI, PLG and TF serum protein markers. They noted that the AHSG, F XIII B and PLG systems appear to be very useful for the characterization of Near Eastern populations. No further details could be obtained.

[Cleve H, Koller A, Patutschnick W, Rodewald A, Nabulsi A. Genetic serum protein polymorphisms in Jordanian Arabs: a pilot study of the systems AHSG, BF, F XIII B, GC, PI, PLG and TF. Gene Geogr. 1992; 6(1-2):31-40.]

[See also: Palestine > Nevo et al., 1992]

Libya

Sebetan (1991) investigated the genetic polymorphism of human plasminogen (PLG) in Libyans by using wide-scale ultrathin-layer polyacrylamide isoelectric focusing with subsequent immunoblotting. Sebetan (1991) found three common and eight variant phenotypes. These were found to be products of two common alleles, PLG*A and PLG*B, and five rare variant ones. Of these variant alleles, four had previously been reported: PLG*A3, PLG*M4, PLG*B1 and PLG*B2. In addition, Sebetan (1991) encountered a new intermediate rare allele, designated PLG*MTripoli (PLG*MT), which although migrated with the PLG*M5 allele in neuraminidase pre-treated samples, was clearly distinguishable in the native state. The estimated allele frequencies for the genes PLG*A, PLG*B, PLG*A3, PLG*MT, PLG*M4, PLG*B1 and PLG*B2 were found to be 0.6409, 0.3091, 0.0182, 0.0045, 0.0091, 0.0045, and 0.0136, respectively. The isolated probability of exclusion in cases of disputed paternity among Libyans is found to be 23.3%.

Palestine

Nevo et al. (1992) reported results of typing Palestinian Arab Moslems and Arab Druze, for seven serum protein genetic variants (BF, F13B, AHSG, GC, PLG, PI, and TF). Data were also compared to results for the same markers in a sample of Jordanians. Gene frequencies for PLG in Moslems (n = 149) and Druze (n = 190) were PLG*A = 0.4597 and 0.5288 and PLG*B = 0.5101 and 0.4188, respectively. Observed rare alleles in various systems indicate gene flow from Europe, Africa, and Asia into the Middle East. Nevo et al. (1992) considered their results to be in relation to available population data in the three adjacent continents.

© CAGS 2024. All rights reserved.